A new discovery and development collaboration has been agreed between Boston, USA-based Verastem Oncology (Nasdaq: VSTM) and Shanghai's GenFleet Therapeutics.
The deal marks an important win for Verastem's new chief executive Dan Paterson, who took the helm at the start of August, replacing Brian Stuglik.
The project is aimed at advancing three oncology discovery programs targeting RAS pathway-driven cancers, using the companies’ expertise in small molecules.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze